Dr. Judd Moul, professor of surgery and director of the Duke Prostate Center, was quoted in a recent NYTimes article. For the first time, two independent clinical trials have showed that two different drugs give certain patients about two more years before their cancer metastasizes. “‘We’re going from rags to riches,'” says Dr. Moul. Read the full article here.
NYTimes: “Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years”
YOU MAY ALSO LIKE
Related Posts
In today’s healthcare landscape, the term “Return on Investment” (ROI) is more than just a financial metric—it’s a reflection of...
The healthcare benefits landscape is undergoing rapid transformation, driven by rising costs, evolving employee needs, and technological advances. For benefits...
Employee benefits are one of the biggest investments organizations make, yet many companies struggle to ensure their workforce understands and...